tirzepatide europe approval Tirzepatide-RUO 30MG EU committee backs extending use

Agenda Co-chairs Dr Luz de Regil Director, Department of Nutrition and Food Safety, WHO and Dr Kirsten Bibbins Domingo Editor-in-Chief, JAMA Moderator Dr Gaya Manori Gamhewage, Director, Department of Communication, WHO Welcoming Dr Luz De Regil Director NFS, WHO and Dr Kirsten Bibbins-Domingo, Editor-in-Chief, JAMA Presentation: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults Dr Francesca Celletti, Senior Advisor Obesity, Department of Nutrition and Food Safety, WHO and Dr

Some users of GLP-1 receptor agonists have reported allergy-like symptoms, including nasal congestion, runny nose, and skin reactions

GLP-1 safety: While FDA-approved for weight management, these medications can cause gastrointestinal side effects and should be monitored by a healthcare provider

Inflammation Balance: By regulating the redox state of cells, it helps maintain a balanced inflammatory response, which is a key selling point for modern immune support formulations

With emphasis placed on understanding its mechanisms, enhancing treatment strategies, and translating scientific findings to clinical practice, we can harness this therapy's therapeutic benefits towards transforming how we manage tendon-related injuries worldwide for improved patient outcomes